中文 | English
Return
Total: 6 , 1/1
Show Home Prev Next End page: GO
MeSH:(Androstenes/therapeutic use*)

2.High IL-23+ cells infiltration correlates with worse clinical outcomes and abiraterone effectiveness in patients with prostate cancer.

Zheng LIU ; Jun-Yu ZHANG ; Yun-Jie YANG ; Kun CHANG ; Qi-Feng WANG ; Yun-Yi KONG ; Bo DAI

Asian Journal of Andrology 2022;24(2):147-153

3.Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer.

Yu-Chao NI ; Jin-Ge ZHAO ; Meng-Ni ZHANG ; Yi-Jun ZHANG ; Zhen-Yu YANG ; Ni CHEN ; Jun-Ru CHEN ; Peng-Fei SHEN ; Guang-Xi SUN ; Xing-Ming ZHANG ; Yong-Hong LI ; Hao ZENG

Asian Journal of Andrology 2022;24(2):154-160

4.A case of metastatic castration-resistant prostate cancer by abiraterone treatment.

Liuxun LI ; Zhi LONG ; Leye HE

Journal of Central South University(Medical Sciences) 2015;40(6):688-692

5.Comparison among measures to prevent intrauterine adhesions after artificial abortion.

Lei LI ; Manman NAI ; Guixiang GAO ; Luwen WANG

Journal of Central South University(Medical Sciences) 2016;41(9):975-978

6.Clinical activity of abiraterone plus prednisone in docetaxel-naοve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer.

Guo-Wen LIN ; Gao-Xiang LI ; Bo DAI ; Ding-Wei YE ; Yun-Yi KONG ; Yue WANG ; Yi-Jun SHEN

Asian Journal of Andrology 2019;21(2):131-136

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 6 , 1/1 Show Home Prev Next End page: GO